Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





LumiraDx Demonstrates Transformative Tests and Technologies

By LabMedica International staff writers
Posted on 13 Nov 2023

LumiraDx (London, UK) is presenting its innovative, next-generation point-of-care diagnostics Platform and broad test menu alongside its Fast Lab Solutions at MEDICA 2023. More...

The LumiraDx Platform is an innovative, next-generation point-of-care system that combines a small, portable instrument, advanced low-cost test strip, and seamless digital connectivity. Its proprietary technology enables it to deliver exceptional point-of-care clinical performance while being simple and easy to use. LumiraDx offers various tests that run on the highly portable LumiraDx Platform, such as the LumiraDx NT-proBNP test which is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick NT-proBNP test currently commercially available. The rapid microfluidic immunofluorescence assay can aid in the diagnosis of congestive heart failure (CHF).

LumiraDx also offers its highly sensitive C-Reactive Protein (CRP) point-of-care antigen test that runs on the portable LumiraDx platform which weighs just over a kilogram. The point of care CRP test can be used in multiple clinical settings to help reduce unnecessary antibiotic prescribing that leads to antimicrobial resistance. From a tiny sample of finger-prick blood, the CRP test gives results within four minutes. Additionally, LumiraDx’s HbA1c test for professional use across multiple care settings is used alongside the LumiraDx Platform. The test monitors known diabetic patients’ HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes. Providing results in less than seven minutes from sample application, the test allows improved efficiency and convenience with on-the-spot diabetes screening and monitoring at the patient’s side.

At MEDICA 2023, LumiraDx is highlighting its LumiraDx INR Test which is an enzyme kinetic assay based on Thrombin activity. The coagulation cascade is activated by the test reagents and INR is calculated from the measured PT-time. Haematocrit is also measured on the strip to ensure patients are within the 25-55% range. The accuracy of the LumiraDx INR Test is comparable to the ACL Elite lab reference method. Another test that supports confident decisions at the point of care with the LumiraDx Platform is the LumiraDx D-Dimer Test which is a rapid microfluidic immunoassay for quantitative determination of D-Dimer. It is the only D-Dimer Test providing fast, accurate, quantitative results in just 6 minutes from a fingerstick blood sample.

Related Links:
LumiraDx 


New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Blood Glucose Test Strip
AutoSense Test
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.